Psyence Competitors
| PBM Stock | USD 2.81 0.15 5.07% |
Psyence Biomedical vs Indaptus Therapeutics Correlation
Significant diversification
The correlation between Psyence Biomedical Ltd and INDP is 0.03 (i.e., Significant diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Psyence Biomedical Ltd and INDP in the same portfolio, assuming nothing else is changed.
Moving together with Psyence Stock
Moving against Psyence Stock
| 0.84 | DSGN | Design Therapeutics | PairCorr |
| 0.84 | IMMP | Immutep Ltd ADR | PairCorr |
| 0.68 | ENGN | enGene Holdings Common | PairCorr |
| 0.55 | 63E | ONWARD MEDICAL BV | PairCorr |
| 0.52 | KYTX | Kyverna Therapeutics | PairCorr |
Psyence Biomedical Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Psyence Biomedical and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Psyence and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Psyence Biomedical does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Psyence Stock performing well and Psyence Biomedical Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Psyence Biomedical's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| AZTR | 4.41 | (0.93) | 0.00 | (0.30) | 0.00 | 6.90 | 36.11 | |||
| NKGN | 4.98 | 2.05 | 0.00 | 11.32 | 0.00 | 20.00 | 68.90 | |||
| GTBP | 5.51 | (0.16) | 0.00 | (0.19) | 0.00 | 10.61 | 51.03 | |||
| REVB | 4.03 | (1.48) | 0.00 | (0.59) | 0.00 | 6.84 | 35.57 | |||
| PTIX | 7.53 | (1.44) | 0.00 | 0.82 | 0.00 | 15.65 | 58.73 | |||
| LIPO | 8.64 | (0.20) | 0.00 | (0.22) | 0.00 | 17.65 | 94.73 | |||
| ELAB | 6.12 | (3.89) | 0.00 | (0.93) | 0.00 | 7.40 | 53.38 | |||
| SPRC | 4.17 | (2.21) | 0.00 | (1.80) | 0.00 | 5.00 | 30.69 | |||
| DRMA | 6.94 | (0.98) | 0.00 | (0.26) | 0.00 | 16.18 | 61.86 | |||
| INDP | 6.11 | (0.59) | 0.00 | (0.08) | 0.00 | 16.13 | 51.64 |
Cross Equities Net Income Analysis
Compare Psyence Biomedical and related stocks such as Azitra Inc, NKGen Biotech Common, and GT Biopharma Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AZTR | (8.9 M) | (8.9 M) | (8.9 M) | (8.9 M) | (8.9 M) | (8.9 M) | (8.9 M) | (8.9 M) | (8.9 M) | (8.9 M) | (8.9 M) | (8.9 M) | (10.7 M) | (11.3 M) | (9 M) | (8.1 M) | (8.5 M) |
| GTBP | 150 K | (3.7 M) | (5.2 M) | (501 K) | (23.5 M) | (21.5 M) | 9.8 M | (144.2 M) | (259.2 M) | (38.6 M) | (28.3 M) | (58 M) | (20.9 M) | (7.6 M) | (13.2 M) | (11.8 M) | (12.4 M) |
| REVB | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 6.2 M | 8.8 M | 16.3 M | 27.6 M | (3.6 K) | (136.4 K) | (12 M) | (10.8 M) | (120.3 K) | (15 M) | (13.5 M) | (12.9 M) |
| PTIX | (476 K) | (476 K) | (1 M) | (1.1 M) | (1.1 M) | (476 K) | (2.3 M) | (2.3 M) | (2.6 M) | (1.8 M) | (2.5 M) | (4.5 M) | (3.6 M) | (5 M) | (5.5 M) | (5 M) | (5.2 M) |
| LIPO | (61.8 K) | (61.8 K) | (61.8 K) | (61.8 K) | (61.8 K) | (61.8 K) | (61.8 K) | (61.8 K) | (61.8 K) | (61.8 K) | (61.7 K) | (1.9 M) | (2.6 M) | (4.6 M) | (5 M) | (4.5 M) | (4.3 M) |
| ELAB | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (784.7 K) | (1.8 M) | (4.3 M) | (6.2 M) | (5.6 M) | (5.3 M) |
| SPRC | (1.7 M) | (3.7 M) | (3.5 M) | 59.4 K | (1.9 M) | (2.5 M) | (2 M) | (6.2 M) | (8.5 M) | (5.4 M) | (3.5 M) | (5.8 M) | (2.6 M) | (5.1 M) | (6.3 M) | (5.7 M) | (5.9 M) |
| DRMA | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (3.2 M) | (7.9 M) | (9.6 M) | (7.8 M) | (12.3 M) | (11.1 M) | (11.6 M) |
| INDP | (5.4 M) | (7.6 M) | (5.2 M) | (5.1 M) | (5.7 M) | (7.2 M) | (13.4 M) | (28.9 M) | (43.5 M) | (47.6 M) | (3.6 M) | (7.7 M) | (14.3 M) | (15.4 M) | (15 M) | (13.5 M) | (14.2 M) |
Psyence Biomedical and related stocks such as Azitra Inc, NKGen Biotech Common, and GT Biopharma Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Psyence Biomedical financial statement analysis. It represents the amount of money remaining after all of Psyence Biomedical Ltd operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Psyence Biomedical Competitive Analysis
The better you understand Psyence Biomedical competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Psyence Biomedical's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Psyence Biomedical's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Psyence Biomedical Competition Performance Charts
Five steps to successful analysis of Psyence Biomedical Competition
Psyence Biomedical's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Psyence Biomedical in relation to its competition. Psyence Biomedical's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Psyence Biomedical in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Psyence Biomedical's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Psyence Biomedical, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Psyence Biomedical position
In addition to having Psyence Biomedical in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Soft Drinks Thematic Idea Now
Soft Drinks
Entities manufacturing and distributing non alcoholic beverages across different markets. The Soft Drinks theme has 12 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Soft Drinks Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Psyence Biomedical Correlation with its peers. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Will Biotechnology sector continue expanding? Could Psyence diversify its offerings? Factors like these will boost the valuation of Psyence Biomedical. Anticipated expansion of Psyence directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Psyence Biomedical data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Psyence Biomedical's market price often diverges from its book value, the accounting figure shown on Psyence's balance sheet. Smart investors calculate Psyence Biomedical's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Psyence Biomedical's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Psyence Biomedical's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Psyence Biomedical should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Psyence Biomedical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.